Objectives and methods: An influenza B virus plasmid-based rescue system was used to introduce site-specific mutations, previously observed in neuraminidase (NA) inhibitor-resistant viruses, into the NA protein of six recombinant viruses. Three mutations observed only among in vitro selected zanamivir-resistant influenza A mutants were introduced into the B/Beijing/1/87 virus NA protein, to change residue E116 to glycine, alanine or aspartic acid. Residue E116 was also mutated to valine, a mutation found in the clinic among oseltamivir-resistant viruses. An arginine to lysine change at position 291 (292 N2 numbering) mimicked that seen frequently in influenza A N2 clinical isolates resistant to oseltamivir. Similarly, an arginine to lysine change at position 149 (152 in N2 numbering) was made to reproduce the change found in the only reported zanamivir-resistant clinical isolate of influenza B virus. In vitro selection and prolonged treatment in the clinic leads to resistance pathways that require compensatory mutations in the haemagglutinin gene, but these appear not to be important for mutants isolated from immunocompetent patients. The reverse genetics system was therefore used to generate mutants containing only the NA mutation.
Introduction
Influenza infection has remained a major threat to public health throughout the world for centuries. Vaccination remains the primary method for prevention of influenza, but vaccine strains must be continually updated and their protective efficacy is limited in patients > 65 years of age, the major target group. An alternative lies in antiviral drugs. Two such drugs, amantadine and rimantadine, block the M2 ion channel protein of influenza A viruses, thereby preventing viral uncoating. However, as influenza B viruses do not contain the M2 protein, they are not affected by the drugs. Amantadine and rimantadine are also associated with certain adverse effects on the gastrointestinal tract and central nervous system, and resistance develops readily. 1, 2 Neuraminidase (NA) inhibitors (NAIs) are a class of antiinfluenza drugs used for both prophylaxis and treatment of influenza virus infections. The drugs are highly potent sialic acid (SA) analogues that selectively target the NA enzyme of both influenza A and B viruses. They interact with NA with a higher affinity than SA in a slow-binding manner, thereby preventing the cleavage of SA molecules from host cell receptors required for viral release. This results in aggregation of progeny virions at the cell surface and prevents viral spread. Two such drugs, zanamivir and oseltamivir (Figure 1 ), display high potency and specificity both in vitro and in vivo [3] [4] [5] [6] [7] [8] and are effective prophylactics. zanamivir and oseltamivir in vitro 12 and in vivo. 13 Results suggest that all three drugs share similar potency and specificity for all subtypes of influenza A and B virus NA.
As with all antiviral drugs, there is the potential problem that drug-resistant variants may exist naturally or may emerge. In tissue culture, NAI-resistant viruses only emerge after several passages in the presence of the drugs. Resistance to NAIs can be conferred by mutations in both haemagglutinin (HA) and NA. 14 Initially, mutations arise in the HA protein, 15, 16 with the generation of NA mutations in further passages. 17 -22 The mechanism for resistance mediated by changes in HA is that mutations at receptor binding sites reduce the binding affinity for SA, enabling virion release from infected cells, even in the presence of an NAI.
NAI resistance can also be conferred by mutations in the NA protein. Changes at four residues, depending on the drug and its interaction with the NA active site, have been described. Two of these residues are 'framework' residues, E119 and H274. The other two are 'functional' residues: R152, which binds directly to sialic acid via the formation of a hydrogen bond to the acetamide group; 23 and R292, a residue that forms part of a catalytic triad of arginine residues responsible for binding to, and changing the conformational shape of, sialic acid. 24 Residue E119 of influenza A virus N1 and N2 NA subtypes interacts with the guanidinyl group of zanamivir ( Figure 1 ). Mutations of this residue to alanine, aspartic acid or glycine confer resistance. 18, 23, 25 Similarly, in the influenza B virus NA protein, the E116G mutation confers resistance. 18, 26 It has been reported that these mutations may lower NA activity by decreasing the NA protein stability. 27 -30 There have also been reports of zanamivirresistant mutant influenza A viruses containing an Arg ! Lys mutation at residue R292 of the N2 NA subtype. 30, 31 However, this R292K mutation is more commonly associated with oseltamivir resistance and is the mutation most frequently observed in resistant N2 subtype mutant viruses isolated from patients, 21, 32 although this mutation is not found in oseltamivir-resistant N1 subtype viruses. The R292K mutation prevents the reorientation of E276, required to accommodate the large hydrophobic pentyl ether group of oseltamivir (Figure 1) . 33 The H274Y mutation also prevents this reorientation event. Therefore, resistance to oseltamivir has also been associated with this mutation, but interestingly only in the N1 subtype viruses. 33, 34 A third mutation, E119V, is associated with oseltamivir resistance. 35, 36 Gubareva et al. 12 showed that resistance to peramivir is also associated with the R292K (influenza A virus N2 subtype) and H274Y (influenza A virus N1 subtype) mutations, as this drug also contains a bulky hydrophobic group that requires reorientation of the NA active site (Figure 1 ). Baum et al. 22 recently reported the generation of a peramivir-resistant influenza B virus which harboured an H274Y change in NA and additional changes in HA. This mutant showed cross-resistance to oseltamivir, but retained sensitivity to zanamivir similar to the A N2 R292K and A N1 H274Y mutants. Gubareva et al. 12 found that an influenza B virus containing an R152K mutation, from the only in vivo selected zanamivir-resistant virus, was resistant to all three drugs. This residue forms a hydrogen bond to the acetamide group of sialic acid. 23 The slight increase in flexibility of the lysine side chain may cause a loss of interaction between this residue and the drugs.
There is no evidence of zanamivir resistance in viruses isolated from normal healthy patients after treatment with the drug. The only case of in vivo zanamivir resistance is that of an 18-month-old immunocompromised child, who acquired an influenza B virus infection and failed to respond to ribavirin treatment. 20 The child was subsequently treated with zanamivir and after 12 days of treatment a virus containing an R152K NA mutation was isolated. This virus also contained a mutation in the HA protein, T198I, which had appeared prior to the NA mutation. In contrast, resistance to oseltamivir occurs in 1%-4% of adults and 4%-8% of the paediatric population. 36 These viruses only contain mutations in the NA protein, suggesting that mutations in HA are not important for in vivo drug resistance. 37 Previous work on NAI resistance has largely centred on influenza A viruses, 12, 17, 19, 21, 28, 30, 31, 35 with only limited work on influenza B virus resistance. 18, 20, 22, 27, 38 This study describes the generation of recombinant influenza B viruses containing NA mutations alone, to study their effects on the NAI susceptibility of influenza B virus in the absence of any compensating HA mutations. This was achieved using an influenza B virus reverse genetics system. Comparison of recombinant viruses with a stable genetic background and in the absence of accompanying HA changes enables growth defects and NA activity decreases to be attributed to the NA mutation alone. Mutant NA proteins have been compared in terms of their enzymatic activity, stability and susceptibility to NAIs. 
Materials and methods

Cells and viruses
293-T cells and Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies) supplemented with 10% fetal calf serum, 1% glutamine (200 mM), 2% non-essential amino acids and 1% penicillinstreptomycin (5000 IU/mL; 5000 mL) at 378C and 5% CO 2 . All viruses were amplified in serum-free DMEM at 348C in the presence of trypsin 2.5 mg/mL. Viruses for NA-STAR NA activity assays were grown in serum-free DMEM lacking phenol red (Life Technologies).
Plasmids and rescue transfections
The pPRNA rescue plasmid 38 was mutated by site-directed mutagenesis (Stratagene) using specific primers. Mutant plasmids were substituted into the influenza B virus rescue system in place of the pPRNA plasmid. Influenza B virus rescue was performed as described previously. 38 Briefly 0.5 mg of pPRPB1, pPRPB2, pPRPA, pPRHA, pPRNP, pPRNA, pPRM, pPRNS, pCIPB1, pCIPB2, pCIPA and 1 mg of pCINP were transfected into 80% confluent 293-T cells on a 12-well plate and incubated at 348C. Sixteen hours after transfection, the 293-T cells were co-cultured with MDCK cells. Each transfection was split into two wells of a six-well plate and incubated at 348C for 8 h. Serum-free DMEM containing trypsin 2.5 mg/mL was added to each well and 1 mU/mL of Vibrio cholerae NA (Roche) was added to one of each duplicate sample. Cells were incubated at 348C until a cytopathic effect was observed $ 68 -72 h post-transfection. All viruses were passaged twice in MDCK cells before use in subsequent experiments.
Flow cytometry
Two wells of 90% confluent Vero cells were infected with each virus at a multiplicity of infection (MOI) of 1 and incubated at 348C with 5% CO 2 for 16 h. Cells were harvested in 1 mL of PBS/EDTA and pooled. Serum-free DMEM (2 mL per well) was added and samples centrifuged at 500 g (2000 rpm) for 3 min. Samples were split in two, with one half being used in the NA-STAR NA activity assay. Cells were resuspended in 500 mL of the anti-FLAG monoclonal antibody at a 1/100 dilution in PBS/0.5% BSA/0.02% sodium azide (PBN) and incubated at room temperature for 1 h on a tube rotator. Cells were washed three times in PBN followed by centrifugation at 500 g for 3 min. Samples were resuspended in 500 mL of anti-mouse FITCconjugated secondary antibody at a 1/100 dilution in PBN and incubated at room temperature for 1 h on a tube rotator. Cells were washed three times, followed by centrifugation at 500 g for 3 min. Samples were fixed in 500 mL of CellFix (Becton Dickinson) and added to 1 mL of FACSflow (Becton Dickinson). The samples were then subjected to flow cytometry in a Becton Dickinson FACScan and results analysed on WinMDI 2.8 software.
NA-STAR neuraminidase activity assay
NA-STAR assays were performed based on the protocol of Buxton et al. 39 Briefly, Vero cells were infected with each virus at an MOI of 1 and incubated at 348C with 5% CO 2 for 16 h. Cells were harvested in 1 mL of PBS/EDTA and resuspended in PBN; 2Â10 6 cells were used in the NA-STAR assay. In a 96-well microtitre plate, serial two-fold dilutions of each sample were prepared in enzyme buffer (325 mM MES/10 mM CaCl 2 , 1:1) and 40 mL of each dilution was transferred to a white Packard Optiplate in duplicate rows. Five microlitres of 100 mM NA-STAR substrate mix (Applied Biosystems, Foster City, CA, USA) was added and the plate was incubated at 378C for 15 min. Fifty-five microlitres of Light Emission Accelerator II (Applied Biosystems) solution was added to each well and the plate was read on the Victor 2 1420 multilabel counter (Wallac, Perkin-Elmer, Boston, MA, USA).
For the IC 50 assay, dilutions of each virus in enzyme buffer that gave a signal-to-noise ratio of no more than 40/1 were made and 40 mL was added to white Packard Optiplates in duplicate rows. Serial four-fold dilutions of zanamivir (GG167) (GlaxoSmithKline), oseltamivir (GS4071) (Roche) or peramivir (RWJ-270201) (Biocryst Pharmaceuticals Inc., Brimingham, AL, USA) were prepared in H 2 O (drug concentrations therefore were in the range 0.55-0.000028 mM) and 10 mL of each dilution was added to all wells. Plates were incubated at room temperature for 30 min. Five microlitres of NA-STAR substrate (100 mM) was added, followed by incubation at 378C for 15 min. Fifty-five microlitres of Light Emission Accelerator II solution was added and the plate was read on the Victor 2 1420 multilabel counter. The results were analysed in Excel using the NA-STAR IC 50 assay template (GlaxoSmithKline).
Multi-cycle virus growth curves
Multi-step growth curve infections were performed in six-well plates of confluent MDCK cells. Cells were infected with virus at an MOI of 0.001 and incubated at 348C for 1 h. Cells were washed in PBS, and 1.5 mL of serum-free DMEM containing trypsin 2.5 mg/mL was added. Supernatant samples were harvested every 12 h until 72 h post-infection and infectivity was determined by plaque assay.
Results and discussion
Generation of mutant influenza B viruses
The recently established influenza B virus plasmid-based reverse genetics system 38 was used to introduce specific mutations into the B/Beijing/1/87 virus NA gene. The pPRNA rescue plasmid, encoding the entire B/Beijing/1/87 virus segment six vRNA, was mutated by site-directed mutagenesis to introduce the following amino acid changes in NA: E116D, E116A, E116V, E116G, R149K and R291K (residues E119, R152, R292, respectively, in N2 virus numbering). Silent non-coding mutations were introduced into each of the plasmids to facilitate detection of possible wild-type revertant viruses. Each plasmid was used in the influenza B virus rescue system in place of the pPRNA plasmid. As it was expected that these mutations would reduce the activity of the NA enzyme, exogenous V. cholerae NA was included in the rescue. In fact, NAE116D was the only virus that required bacterial NA for its recovery, although on subsequent passage exogenous NA was not required. The plaque size of mutant NAE116D was, however, smaller compared with the wild-type virus and the other mutants, indicating that NA activity was significantly altered in this mutant.
It is possible to introduce a FLAG epitope into the stalk region of the influenza A virus NA protein. 40 Viruses were also rescued in which a FLAG epitope was inserted into the stalk region of rescued B/Beijing/1/87 virus NA for subsequent flow cytometry analysis of infected cell surface NA expression. The FLAG epitope replaced codons 42-49 of the B/Beijing/1/87 virus NA. It also resulted in a premature stop codon in the NB open reading frame (ORF), resulting in a 47-amino-acid NB protein, a truncation of 53 amino acids. However, this is unlikely to be detrimental to replication in vitro since viruses completely lacking the NB ORF are viable in tissue culture (D. Jackson & W. Barclay, unpublished data). 41 Viruses containing the FLAG epitope, in conjunction with each of the single point mutations in NA, were rescued. The NA and HA genes of all 14 recovered viruses were fully sequenced, to confirm the presence of the desired mutations and the lack of non-specific or compensatory changes.
Determination of enzymatic NA activity of mutant NA proteins
Vero cells were infected at 348C with each of the seven mutant viruses containing the FLAG epitope, and NA expression and activity were measured 16 h post-infection by flow cytometry and NA-STAR assays 39 ( Table 1 ). The results show that five of the six NA mutant viruses displayed similar cell surface NA expression levels to the NA-FLAG wild-type virus, with the exception being the E116D mutant, which displayed an increase in NA expression. This was subsequently proven to be due to a higher titre of virus stock, resulting in a greater MOI being used in this experiment. The E116A and E116V mutations resulted in increased activity compared with wild-type NA. The E116D mutation resulted in a decrease in NA activity, despite the fact that the glutamic acid to aspartic acid mutation is a relatively conservative change. Accordingly, this was the only mutant virus that required exogenous bacterial NA for its recovery. The R291K mutation resulted in the largest reduction in NA activity to only 6% of the NA-FLAG wild-type virus.
Determination of NA stability for mutant NA proteins
Mutations within the NA protein at positions that confer resistance to NAIs can affect the stability of the protein, which is reflected by a decrease in enzyme activity following incubation of mutant NA at higher temperatures. 28 -30,42 The NA activity of influenza B/Beijing/1/87 mutants was measured by NA-STAR assay after incubation at one of three temperatures, 48C, 378C or 508C for 2 h. No NA activity was measurable for any sample at 508C, presumably as a result of denaturation of the protein. The decrease in NA activity following incubation at 378C compared with 48C was determined ( Table 1 ). The data show that the wild-type protein is the most stable of all assayed proteins. It is interesting to note that the E116V NA enzyme is relatively stable, even though a glutamic acid to valine mutation encompasses both a reduction in the size of the side chain as well as a difference in charge. The effects of the E116G mutation on NA protein stability in the context of both influenza A and B viruses have previously been reported. 27 -30 The results here confirm previous findings that the reduction in relative NA activity of this mutant is not due to a decrease in NA activity but to a less stable protein. The R291K mutation resulted in a significant decrease in protein stability, whereas in the context of influenza A virus NA this mutation does not affect protein stability to the same extent. 30 The stability of the NAR149K NA enzyme was only 3.9% that of wild-type NA, therefore despite a high relative activity (82%), this virus is likely to be extremely attenuated in vivo. There are clear discrepancies for some mutants between the relative NA activity when expressed by single cycle infection of Vero cells at 348C and relative reduction in NA activity after additional incubation at 378C. These differences in protein stability may contribute to replication efficiency in multiple cycle infections in cell culture or in the patient.
Effects of NA point mutations on the growth characteristics of mutant viruses
Analysis of multi-cycle replication of these viruses showed that, with the exception of a virus containing the E116G mutation, all mutants displayed varying levels of attenuation in tissue culture (Figure 2 ). Similar data were obtained using the set of recombinant viruses carrying the FLAG tag (data not shown).
The finding that influenza B viruses containing an E116G mutation can replicate as efficiently as the wild-type virus has previously been reported. 27, 38 The NA protein containing the E116G mutation displayed 60% relative NA activity and 57% protein stability compared with wild-type virus. Therefore this level of enzyme activity must be sufficient to generate a virus with growth kinetics similar to wild-type virus in cell cultures. Recombinant viruses bearing the E116A and E116V mutations were attenuated up to 10-fold in comparison to wild-type virus. This may be due to an overactive NA protein, as the relative 43 The NAE116D virus was significantly attenuated in comparison with the wild-type virus. This mutation reduced the enzymatic activity of the protein to the extent that the NAE116D virus required exogenous bacterial NA for its recovery. This may be due to a low relative NA activity (15% of that of Brec virus) and only 71% NA enzyme stability compared with the wild-type virus NA protein.
Residue R149 is highly conserved among all known NA proteins and is predicted to be important in the binding of sialic acid. Lentz et al. 44 demonstrated that an NA protein (N2 subtype) containing an Arg ! Lys mutation at this position lost all NA activity. The NAR149K virus was significantly attenuated in comparison to the Brec virus (Figure 2 ). This may be due to the low stability of the enzyme, as it displayed 82% relative NA activity compared with that of the Brec virus NA protein. This result suggests that NA protein stability is a major factor in determining virus viability. The B/Memphis/12/97 virus, 20 which contained the R149K mutation, also contained a compensating HA mutation, which may have accounted for the viability of the virus.
Replication of the NAR291K virus was significantly attenuated compared with wild-type virus, and did not attain its peak titre until 60 h after infection, 12 h later than all the other viruses. This may be due to the reduction in NA activity to only 6% of wild-type levels. The recovery of titre at the later time points was not due to the R291K mutation reverting to wild-type sequence: both segment four and six vRNA from 60 and 72 h time point supernatant samples were analysed for sequence changes. It was previously shown by Gubareva et al. 30 that an influenza A virus (N2 subtype) containing this mutation grew to titres similar to wild-type virus but displayed a reduction in NA activity. The results in this study support this finding. However, the reduction in NA activity and stability of B/Beijing/1/87 R291K virus is greater than previously observed for influenza A viruses.
Although the attenuation of any individual mutant virus can be accounted for by a comparison of NA protein stability and activity with that of wild-type, it is not always possible to correlate relative fitness of mutant viruses with the NA enzyme data. For example, it is unclear why the activity and stability values of the NAE116D virus NA protein were greater than those of the NAR291K virus NA protein, whereas the NAR291K virus grew to far higher titres. This suggests that other factors might be involved in determining the fitness of NA mutant viruses.
Determination of IC 50 values for mutant viruses in the presence of NAIs
The effects of NA mutations on susceptibility to NAIs were determined by measuring the IC 50 of each recombinant virus in the presence of each of the three different NAIs, zanamivir, oseltamivir and peramivir ( Figure 1 ; Table 2 ). The IC 50 value of each mutant virus was expressed as fold-increase in IC 50 compared with Brec wild-type virus. All mutant viruses displayed increased IC 50 results for each drug when compared with wildtype virus. Results suggest that the NAI resistance of the NA mutant viruses is similar to that previously observed for mutant viruses and is probably determined by a reduction in interaction between each drug and the NA active site. The NA gene of the B/Beijing/1/87 virus has been crystallized, 45 as has its complex with sialic acid. 46 Figure 3 shows the predicted interactions between B/Beijing/1/87 NA residues E116, R149 and R291 with zanamivir. Residue E116 interacts with the guanidinyl group at the 4-position of zanamivir. 27 This group, which is also shared by peramivir, is proposed to form a salt bridge with 'framework' residues E116 and E227. 47 This is why zanamivir resistance mutations predominantly arise at residue E119 in influenza A virus NA, which corresponds to B/Beijing/1/87 virus NA residue E116. 32 We show here that mutations at E116 to aspartic acid, alanine, valine or glycine are possible in the context of infectious influenza B virus. The shortening of the side group of this residue resulting from the change from glutamic to aspartic acid or to alanine, may prevent the interaction with the guanidinium group of zanamivir or peramivir and thus explain the high-level resistance of the NAE116D and NAE116A recombinant viruses to those drugs. In addition, mutations at this amino acid can also confer resistance to 4-amino-Neu5Ac2en by abrogating an interaction with the amino group at the 4-position of the drug. 32 This may therefore explain the high-level resistance of these mutant viruses to oseltamivir (Table 2) , as it also contains an amino group at the same position.
Interestingly, influenza B recombinant viruses containing the E116V mutation are susceptible to zanamivir but not peramivir in spite of structurally based predictions that this mutation should confer resistance to both drugs. Previous studies have shown that this mutation in the influenza A virus NA conferred resistance to oseltamivir. 35 Our data confirm this finding. The E116G mutation has been shown on numerous occasions to confer zanamivir resistance. 17, 18, 27, 38 Again this is probably due to the shortening of the side group of the residue preventing an interaction with the drug, and it is not surprising that the NAE116G virus is also resistant to peramivir. An influenza A virus containing the E119G mutation in the N2 NA subtype, reported by Gubareva et al. 30 displayed only low-level resistance to 4-aminoNeu5Ac2en. Accordingly, the NAE116G influenza B virus displayed less resistance to oseltamivir than to the other two drugs.
R149 is a 'functional' residue that directly interacts with sialic acid, forming a hydrogen bond to the acetamide group (reviewed in ref. 23) (Figure 3) . As all three NAIs contain the acetamide group, NA altered at this residue might be expected to display global resistance to all the drugs. Indeed, this prediction was borne out in a survey by Gubareva et al. 12 Our data suggest that in the context of the B/Beijing/1/87 NA the R149K mutation results in a high level of resistance to oseltamivir and peramivir, but only moderate resistance to zanamivir. The reasons why the NAR149K mutant virus shows only moderate resistance to zanamavir are not clear; however, similar results were also obtained by McKimm-Breschkin et al. 48 Figure 3 shows that in the B/Beijing/1/87 NA, residue R291 may interact with the glycerol side group of zanamivir and computational analysis predicts that this may be due to the formation of a hydrogen bond, which was previously suggested by Burmeister et al. 46 to support binding of R291 to sialic acid. In order for oseltamivir or peramivir to bind in the influenza A virus NA active site, a conformational change has to take place to accommodate the bulky hydrophobic group of these two drugs. The reorientation of residue E276 allows it to form a salt link with R224, which thereby creates the hydrophobic pocket required to accommodate the large hydrophobic group of the drugs (reviewed in ref. 23 ). However, it is not known whether this reorientation event occurs in the influenza B virus NA active site, as the region surrounding E276 is naturally hydrophobic; therefore, this event would be energetically less favourable. 12 A peramivir-resistant influenza B virus with an H274Y change in NA has been reported 22 and this mutant showed cross-resistance to oseltamivir, but retained sensitivity to zanamivir, similar to the A N2 R292K and A N1 H274Y mutants. An R292K mutation in the influenza A virus NA active site prevents the reorientation event, thereby preventing the binding of oseltamivir or peramivir, leading to drug resistance. Influenza A viruses (N2 subtype) containing an R292K mutation have been isolated during treatment with oseltamivir 35 and in vitro in the presence of oseltamivir, 21 zanamivir 30 and peramivir 13 (reviewed in ref. 23 ). These viruses tend to display high-level resistance to oseltamivir and peramivir but low-level resistance to zanamivir. The data in Table 2 show that the characteristics of influenza B virus NA containing alterations at this residue are similar, which makes it likely that the reorientation event may indeed occur in the influenza B virus NA active site. It can be concluded that some of the mutations studied here rendered influenza B virus resistant to more than one NAI. However, mutations E119V and R292K, found in oseltamivir-treated patients infected with influenza A N2 viruses, did not cause resistance to zanamivir in influenza B viruses, offering alternative treatment options.
The structurally designed NA inhibitors closely resemble the natural NA substrate (SA) and data obtained so far indicate that resistance requires changes in the highly conserved active site of NA. Our data showed that all mutants displayed significant alteration in the relative enzymatic NA activity and stability of NA, which seem to be tolerated for replication in tissue culture, but might significantly affect replication in man. Accordingly, it has been shown previously that mutants isolated from oseltamivir-treated patients could be propagated in tissue culture, but reverted immediately in infected animals. 49 The development of resistance during an acute, self-limiting viral infection will be different from a chronic viral infection with a limited number of viral replication cycles and opportunities to generate resistance. Future monitoring of NAI treatment will show whether resistant mutants are able to spread from patient to patient, are maintained among circulating viruses and can indeed cause a problem for NAI treatment.
